Abivax SA
PAR:ABVX

Watchlist Manager
Abivax SA Logo
Abivax SA
PAR:ABVX
Watchlist
Price: 105.2 EUR 1.35%
Market Cap: 8.2B EUR

Abivax SA
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Abivax SA
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Abivax SA
PAR:ABVX
Net Income (Common)
-€248m
CAGR 3-Years
-66%
CAGR 5-Years
-51%
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Net Income (Common)
-€120.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Nanobiotix SA
PAR:NANO
Net Income (Common)
-€51.4m
CAGR 3-Years
-6%
CAGR 5-Years
-2%
CAGR 10-Years
-15%
Inventiva SA
PAR:IVA
Net Income (Common)
-€311m
CAGR 3-Years
-77%
CAGR 5-Years
-65%
CAGR 10-Years
N/A
Cellectis SA
PAR:ALCLS
Net Income (Common)
-$76.4m
CAGR 3-Years
24%
CAGR 5-Years
0%
CAGR 10-Years
-10%
DBV Technologies SA
PAR:DBV
Net Income (Common)
-$123m
CAGR 3-Years
-17%
CAGR 5-Years
14%
CAGR 10-Years
-16%
No Stocks Found

Abivax SA
Glance View

Market Cap
8.2B EUR
Industry
Biotechnology

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

ABVX Intrinsic Value
16.34 EUR
Overvaluation 84%
Intrinsic Value
Price

See Also

What is Abivax SA's Net Income (Common)?
Net Income (Common)
-248m EUR

Based on the financial report for Jun 30, 2025, Abivax SA's Net Income (Common) amounts to -248m EUR.

What is Abivax SA's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-51%

Over the last year, the Net Income (Common) growth was -12%. The average annual Net Income (Common) growth rates for Abivax SA have been -66% over the past three years , -51% over the past five years .

Back to Top